Efficacy and safety of remimazolam besylate versus propofol during hysteroscopy: single-centre randomized controlled trial (vol 21, 156, 2021)

被引:18
|
作者
Zhang, Xiaoqiang [1 ]
Li, Shuang [1 ]
Liu, Jing [1 ]
机构
[1] Mengcheng Cty 1 Peoples Hosp, Dept Anaesthesiol, Mengcheng 233500, Anhui, Peoples R China
关键词
Anaesthesia; Benzodiazepine; Hysteroscopy; Propofol; Remifentanil; Remimazolam besylate;
D O I
10.1186/s12871-021-01390-x
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Background: Remimazolam besylate is a newer benzodiazepine with characteristics of quick onset of effects, short maintenance and recovery times without accumulation in tissues. This trial was conducted to confirm the efficacy and safety of remimazolam besylate versus propofol during hysteroscopy. Methods: Patients undergoing hysteroscopy were randomly assigned to either the remimazolam (Group R) or the propofol group (Group P). Group R was administered an induction dose of 0.2 mg/kg and a maintenance dosage of 1.0 mg/kg/h. In Group P, propofol was started at 1.5–2.0 mg/kg and then maintained at 3.0–6.0 mg/kg/h. After remimazolam besylate or propofol induction, remifentanil was infused using a target-controlled infusion system with a target concentration of 1.5 ng/ml and titrated during the procedure. The incidence rates of injection pain, low oxygen saturation (SpO2) and adverse effects in both groups were compared. Results: Eighty-two patients were included in this study. The incidence of adverse events in Group R (3.7%) was significantly lower than that in Group P (36.6%) (p < 0.001). The incidence of injection pain in Group P (80.5%) was much higher than that in Group R (2.4%) (p < 0.001). The incidence of other adverse events, such as low SpO2, bradycardia, and hypotension in Group R was lower than that in Group P (p < 0.05). Conclusions: Remimazolam besylate proves to be a safer alternative for anesthesia during hysteroscopy. Moreover, adverse events caused by propofol, such as low SpO2 and injection pain, are largely avoided. Trial registration: This study was approved by the Clinical Research Ethics Committee of Mengcheng County No. 1 People’s Hospital (2020MYL20003) and registered at http://www.chictr.org.cn (15/09/2020, ChiCTR-2000038252). The study protocol followed the CONSORT guidelines. The study protocol was performed in the relevant guidelines. © 2021, The Author(s).
引用
收藏
页数:2
相关论文
共 47 条
  • [1] The efficacy and safety of remimazolam besylate, ciprofol, and propofol during hysteroscopy
    Shan, Weifeng
    Gao, Shuying
    Ai, Mengting
    Lan, Haiyan
    Duan, Gongchen
    Dong, Xiaoli
    Xu, Qiaomin
    Wu, Yini
    Wu, Jimin
    FRONTIERS IN PHARMACOLOGY, 2025, 15
  • [2] Remimazolam-remifentanil causes less postoperative nausea and vomiting than remimazolam-alfentanil during hysteroscopy: a single-centre randomized controlled trial
    Zhang, Xiaoqiang
    Li, Shuang
    Liu, Jing
    BMC ANESTHESIOLOGY, 2023, 23 (01)
  • [3] Remimazolam-remifentanil causes less postoperative nausea and vomiting than remimazolam-alfentanil during hysteroscopy: a single-centre randomized controlled trial
    Xiaoqiang Zhang
    Shuang Li
    Jing Liu
    BMC Anesthesiology, 23
  • [4] Efficacy and safety of remimazolam tosylate in hysteroscopy: A randomized, single-blind, parallel controlled trial
    Zhang, Shuoya
    Wang, Jiagao
    Ran, Ran
    Peng, Yuchuan
    Xiao, Yun
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2022, 47 (01) : 55 - 60
  • [5] Comparison of the Safety and Efficacy of Remimazolam Besylate versus Dexmedetomidine for Patients Undergoing Fiberoptic Bronchoscopy: A Prospective, Randomized Controlled Trial
    Xu, Huiying
    Wang, Lizhen
    Zhu, Wenchao
    Ren, Chunguang
    Liu, Guoying
    Liu, Yanchao
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2024, 18 : 2317 - 2327
  • [6] The Efficacy and Safety of Remimazolam Besylate Combined with Esketamine for Outpatient Colonoscopy: A Prospective, Randomized, Controlled Clinical Trial
    Li, Wei
    Zhao, Jun
    Hao, Ruiping
    Wang, Shujuan
    Chen, Ming
    Liu, Huijun
    Qi, Le
    Hao, Zaijun
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2023, 17 : 2875 - 2887
  • [7] Safety and efficacy of remimazolam besylate in patients undergoing colonoscopy: A multicentre, single-blind, randomized, controlled, phase III trial
    Wang, Ximei
    Hu, Xiaolei
    Bai, Nianyue
    Li, Lie
    Zhang, Min
    Cheng, Zhigang
    Guo, Qulian
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [8] Comparison of sedation with dexmedetomidine vs propofol during hysteroscopic surgery: Single-centre randomized controlled trial
    Tanriverdi, Tugba Bingol
    Koceroglu, Ikbal
    Devrim, Sibel
    Celik, Melek Gura
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2019, 44 (02) : 312 - 317
  • [9] Efficacy and safety of remimazolam tosilate versus propofol in patients undergoing day surgery: a prospective randomized controlled trial
    Luo, Wenchen
    Sun, Minli
    Wan, Jie
    Zhang, Zhenyu
    Huang, Jian
    Zhang, Jinlin
    Xiong, Wanxia
    Xia, Lirong
    Xu, Peiyao
    Miao, Changhong
    Zhang, Xuesong
    Liu, Mingyue
    Zhong, Jing
    BMC ANESTHESIOLOGY, 2023, 23 (01)
  • [10] Efficacy and safety of remimazolam tosilate versus propofol in patients undergoing day surgery: a prospective randomized controlled trial
    Wenchen Luo
    Minli Sun
    Jie Wan
    Zhenyu Zhang
    Jian Huang
    Jinlin Zhang
    Wanxia Xiong
    Lirong Xia
    Peiyao Xu
    Changhong Miao
    Xuesong Zhang
    Mingyue Liu
    Jing Zhong
    BMC Anesthesiology, 23